Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

Summary

This study is designed as a proof of concept of KRP203 for induction of remission in ulcerative colitis (UC). The purpose of this study is to evaluate clinical benefit of KRP203 in subjects with moderately active refractory ulcerative colitis. The study will provide safety and tolerability data in this subject population up to eight weeks of treatment with KRP203. Additionally, this study will evaluate the duration of a clinical response to KRP203 by following up responding subjects for an additional 12 weeks.

Timeline

Start

2010-12

Primary completion

2012-05

Completion

2012-05

Drugs

Indications